From the Hypotheses to Clinical Evidence in Retinal Therapy
| Autor: | Fernando Antonio Arevalo Suarez, J. Fernando Arevalo, Bradley Beatson |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
intravitreal bevacizumab
medicine.medical_specialty genetic structures medicine.medical_treatment Diabetic macular edema vitrectomy Vitrectomy Disease law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Ophthalmology medicine Intravitreal bevacizumab vascular endothelial growth factor business.industry Retinal Diabetic retinopathy tractional retinal detachment RE1-994 medicine.disease eye diseases Vascular endothelial growth factor diabetic retinopathy chemistry Perspective 030221 ophthalmology & optometry sense organs diabetic macular edema business 030217 neurology & neurosurgery |
| Zdroj: | Journal of Ophthalmic & Vision Research, Vol 16, Pp 287-290 (2021) Journal of Ophthalmic & Vision Research |
| ISSN: | 2008-322X 2008-2010 |
| Popis: | The off-label, therapeutic use of intravitreal bevacizumab (IVB) in vascular retinal diseases such as diabetic macular edema and proliferative diabetic retinopathy (PDR) has increased significantly due to its ability to reduce retinal neovascularization and slow progression of disease. Here, we will review the literature and investigative developments on the use of IVB as a preoperative adjuvant to vitrectomy in severe PDR, specifically focusing on its ability to reduce intra- and postoperative complications and its risk for progression or development of traction retinal detachment. In particular, this review will highlight the natural progression of evidence from case series and observations to prospective, randomized clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|